• LAST PRICE
    6.02
  • TODAY'S CHANGE (%)
    0.00 (0.00%)
  • Bid / Lots
    6.00/ 0
  • Ask / Lots
    6.02/ 0
  • Open / Previous Close
    0.00 / 6.02
  • Day Range
    ---
  • 52 Week Range
    Low 1.52
    High 22.82
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 5.84
TimeVolumePRVB
09:32 ET12425.84
09:34 ET2005.84
09:36 ET7305.88
09:45 ET3005.9
09:50 ET2005.88
09:52 ET6005.86
09:54 ET37985.9
09:56 ET45165.88
09:57 ET3005.9
10:01 ET54635.97
10:03 ET3005.95
10:06 ET1005.97
10:08 ET21215.98
10:10 ET100706.03
10:15 ET21005.97
10:17 ET5005.97
10:19 ET4005.98
10:21 ET59005.96
10:24 ET24006
10:26 ET68406.06
10:28 ET18006.01
10:30 ET46936.03
10:39 ET6005.95
10:42 ET2006.02
10:44 ET23005.97
10:48 ET7005.98
10:50 ET25005.96
10:53 ET13005.94
10:57 ET1005.97
11:02 ET4805.98
11:06 ET15705.9
11:11 ET1005.98
11:26 ET40005.95
11:27 ET101005.93
11:29 ET74005.86
11:31 ET3005.88
11:33 ET5005.91
11:36 ET2005.91
11:40 ET3005.99
11:42 ET2006.02
11:44 ET2005.98
11:45 ET1006.02
11:47 ET1006.02
11:49 ET1005.99
11:51 ET4005.99
11:54 ET7555.99
12:02 ET1005.94
12:03 ET1005.94
12:07 ET1005.95
12:09 ET6965.95
12:12 ET2005.94
12:14 ET7005.95
12:16 ET6005.95
12:18 ET9005.95
12:21 ET2005.95
12:23 ET14005.95
12:32 ET1005.98
12:34 ET1005.93
12:48 ET26005.95
12:50 ET2005.94
12:52 ET1605.93
12:56 ET2505.93
01:01 ET1005.97
01:03 ET1005.93
01:08 ET1005.93
01:10 ET6005.95
01:12 ET2075.95
01:14 ET2005.95
01:15 ET3005.95
01:17 ET2005.95
01:19 ET2005.97
01:21 ET5005.97
01:24 ET3005.97
01:26 ET1005.98
01:30 ET22006.01
01:32 ET2006.01
01:35 ET21926.04
01:37 ET1006.06
01:39 ET12006.06
01:42 ET4006.09
01:44 ET12006.06
01:46 ET15226.02
01:50 ET1006.01
02:00 ET7386.02
02:04 ET3005.99
02:08 ET1005.96
02:09 ET2005.96
02:15 ET1005.93
02:27 ET2005.94
02:29 ET10805.96
02:31 ET10005.98
02:33 ET5005.95
02:36 ET20005.95
02:38 ET3005.96
02:40 ET23005.97
02:44 ET93005.98
02:45 ET7005.98
02:47 ET4006
02:51 ET2006
02:54 ET26506
02:56 ET41006.06
02:58 ET2006.09
03:00 ET1006.09
03:02 ET3006.08
03:03 ET72705.98
03:05 ET1005.97
03:07 ET1005.97
03:09 ET3146
03:16 ET3005.98
03:18 ET8746.01
03:21 ET8006.01
03:23 ET10365.99
03:25 ET1006
03:27 ET7006
03:30 ET12086.02
03:32 ET3006.01
03:34 ET5006
03:36 ET1006
03:38 ET21006.03
03:39 ET7006.05
03:41 ET31836.05
03:43 ET10006.05
03:45 ET32556.08
03:48 ET30006.07
03:50 ET66656.06
03:52 ET15576.05
03:54 ET17016.07
03:56 ET29636.06
03:57 ET55946.03
03:59 ET47456.01999998092651
Data delayed at least 15 minutes.

Sep 30, 2019

Sep 26, 2019

7:28AM ET on Thursday Sep 26, 2019 by Thomson Reuters

Sep 24, 2019

7:16AM ET on Tuesday Sep 24, 2019 by Thomson Reuters

Sep 19, 2019

5:16PM ET on Thursday Sep 19, 2019 by MT Newswires
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesPRVB
Provention Bio Inc
282.1M
---
---
United StatesCYCN
Cyclerion Therapeutics Inc
282.4M
---
---
United StatesUROV
Urovant Sciences Ltd
287.0M
---
---
United StatesGERN
Geron Corp
280.8M
---
---
United StatesNCNA
NuCana PLC
214.3M
---
---
United StatesKNSA
Kiniksa Pharmaceuticals Ltd
290.2M
---
---
As of 2019-10-18

Company Information

Provention Bio, Inc. is a clinical-stage biopharmaceutical company that develops therapeutics targeting immune-mediated diseases. The Company aims at developing therapies for disease that include type one diabetes (T1D), Crohn’s disease, ulcerative colitis, lupus and other viral diseases. The Company’s principal product candidates include PRV-031, PRV-6527, PRV-300, PRV-3279, and PRV-0101.PRV-031 is a product candidate in its Phase III clinical trial that is developed for the interception of T1D. PRV-6527 is an oral CSF-1R inhibitor for the treatment of Crohn’s disease. PRV-300 is developed for the treatment of ulcerative colitis. PRV-3279 is developed to treat lupus disease. PRV-101 is a multivalent coxsackie virus (CVB) vaccine for the prevention of acute CVB and the prevention of the onset of T1D.

Contact Information

Headquarters
PO Box 666OLDWICK, NJ, United States 08858-0666
Phone
908-428-9136
Fax
302-636-5454

Executives

President, Chief Executive Officer, Director
Ashleigh Palmer
Chief Financial Officer
Andrew Drechsler
Chief Operating Officer, Chief Medical Officer
Eleanor Ramos
Chief Scientific Officer, Director
Francisco Leon
Director
Jeffrey Bluestone

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$282.1M
Revenue (TTM)
$0.00
Shares Outstanding
46.9M
Dividend Yield
0.00%
Annual Dividend Rate
0.00 USD
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-0.94
Book Value
$1.60
P/E Ratio
---
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.